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ABSTRACT 
Epidemiological studies suggest that diet can alter prostate cancer risk. This study 
aimed to establish the feasibility and acceptability of dietary modification in men at 
increased risk of prostate cancer. Men were invited with a prostate specific antigen 
(PSA) level of 2.0-2.95 ng/mL or 3.0-19.95 ng/mL with negative prostate biopsies. 
Randomization (3x3 factorial design) to daily green tea and lycopene: green tea drink (3 
cups, unblinded) or capsules (blinded, 600 mg flavan-3-ol ()-epigallocatechin-3-gallate 
(EGCG) or placebo) and lycopene-rich foods (unblinded) or capsules (blinded, 15 mg 
lycopene or placebo) for six months. Primary endpoints were randomization rates and 
intervention adherence (blinded assessment of metabolites) at six months with 
secondary endpoints of acceptability (from interviews), safety, weight, blood pressure 
and PSA. A total of 133/469 (28.4%) men approached agreed to be randomized and 
132 were followed-up (99.2%). Mean lycopene was 1.28 (95% confidence intervals (CI) 
1.09, 1.50, p = 0.003) times higher in the lycopene capsule group and 1.42 (95% CI 
1.21-1.66, p<0.001) times higher in the lycopene-enriched diet group compared to 
placebo capsules. Median EGCG was 10.7 nM (95% CI 7.0, 32.0) higher in in the active 
capsule group and 20.0 nM (95% CI 0.0, 19.0) higher in the green tea drink group 
compared with placebo capsules (both p<0.001). All interventions were acceptable and 
well tolerated although men preferred the capsules. Dietary prevention is acceptable to 
men at risk of prostate cancer. This intervention trial demonstrates that a 
chemoprevention clinical trial is feasible.  
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Introduction 
Prostate cancer is the commonest non-cutaneous male malignancy worldwide with 
higher incidence in developed countries, in part due to screening with prostate specific 
antigen (PSA)(1). Around three quarters of men with an elevated PSA will not have 
cancer diagnosed immediately so safe and effective chemoprevention would be 
beneficial as they are at risk of future diagnosis (2). Randomized controlled trials (RCT) 
of prostate cancer prevention have included pharmaceutical and nutritional agents but 
with limited success. Finasteride (a 5-alpha-reductase inhibitor (ARI)) reduced prostate 
cancer risk in an RCT but the increase of high grade tumors in the finasteride group and 
other adverse effects prevented licensing (3).  Dutasteride (another ARI) also showed a 
lower incidence of prostate cancer but with a small excess of cardiac failure events (14 
extra cases in 4,105 men, p = 0.03) (4) More recently, the risk of higher grade cancers 
on 5-ARIs was not confirmed although there is an increased sexual side effect profile 
(5). The lower prostate cancer incidence in a lung cancer prevention trial for smokers 
with vitamin E (6) and in a selenium trial for melanoma patients (7) informed the design 
of the selenium and vitamin E phase III SELECT trial. However, despite being a well-
conducted RCT with an intensive recruitment strategy and high enrolment of ethnic 
minority participants there were no benefits at a five-year interim analysis of SELECT. 
The trial was stopped prematurely and subsequently a higher prostate cancer incidence 
was shown in the vitamin E group (8). 
 
Promising dietary chemoprevention agents based on pre-clinical and 
observational studies include lycopene, the major carotenoid in tomatoes. Lycopene is 
an active singlet oxygen quencher which assists DNA repair mechanisms (9). The 
WCRF/AICR systematic review categorized lycopene as “probable for decreased 
prostate cancer risk” (10) which was revised to “limited - no conclusion” in 2014 (11) 
One of the few RCTs of lycopene supplementation for prostate cancer prevention in 
Afro-Caribbean men with high grade prostatic intraepithelial neoplasia (HGPIN, a 
potential prostate cancer precursor) did not alter PSA levels (12). However, participants 
were not blinded, follow-up was only four months and the acceptability of lycopene was 
not assessed in this trial.  
 
Prostate cancer incidence in Asian countries with high consumption of green tea 
such as Japan is lower than in western countries (13). Epigallocatechin-3-gallate 
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(EGCG) is the most abundant and potent catechin in green tea with anti-tumor activities 
on inflammatory, insulin growth factor and androgen signalling pathways (14). The 
WCRF/AICR review found “limited- no conclusions” possible for green tea for prostate 
cancer although a more recent review found it preventative (15). A recent small trial of 
EGCG capsules in men with HGPIN concluded that there was no difference in prostate 
cancer rates on re-biopsy at one year, although PSA levels were reduced by around 1 
ng/ml and the capsules were well tolerated (16). 
 
Evidence is now required from RCTs of dietary interventions for prostate cancer 
prevention to detect clinical benefits and harms. However, given the paucity of 
randomized trials we firstly aimed to investigate the acceptability and feasibility of 
dietary modification and supplementation for green tea and lycopene in men at 
increased risk of prostate cancer in a placebo-controlled trial. Here we report the 
ProDiet (Prostate Diet) feasibility trial primary and secondary endpoints. 
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Materials and Methods 
Study design 
This was a placebo-controlled phase II randomized trial which compared green tea and 
lycopene dietary modification and capsules in men with PSA results between 2.0 and 
2.974 ng/mL, or between 2.975-19.95 ng/mL with a negative biopsy. The study was 
approved by the UK Healthcare Research Authority Trent Multicentre Research Ethics 
Committee (08/H0405/61), conducted according to Declaration of Helsinki, 1964 and 
the trial number is ISCTRN 95931417. 
 
Recruitment and eligibility 
Men who had participated in the Prostate testing for cancer and Treatment 
(ProtecT) trial at nine family practices in a UK city were invited to the ProDiet study 
between 2009-2010. The ProtecT trial (ISCTRN 20141297) is a population-based 
randomized controlled trial of treatments for localized prostate cancer (17) In brief, 
82,849 men aged 50-69 years were invited for PSA testing in nine centers and those 
with a raised PSA result were invited for standardized prostate biopsies. No ProtecT 
tests were offered if the PSA result was below 3.0 ng/mL or for negative biopsy results.  
Men attended a ProDiet appointment at their family practice with a study nurse 
who assessed eligibility, explained the potential risks and benefits of participation and 
obtained written consent. Men were excluded with a history of allergies to lycopene-
containing foods or green tea; current or prior prostate cancer; major co-morbidities or 
5-ARI medication.  
 
Randomization and blinding 
 Participants were randomly allocated to one of three lycopene interventions and 
to one of three green tea interventions using a blocked random allocation (1:1:1 
ratio)(generated by the trial statistician [CM] using the Stata uniform() function) so that 
around 14 men were allocated to each of the nine lycopene and green tea intervention 
combinations. The intention had been to stratify the allocation by baseline PSA; 
however, this was impractical with opaque envelopes for allocation. 
The allocation was concealed from the study nurse recruiting individuals until the 
participant’s details were logged electronically with the research centre, the nurse then 
opening the next numbered envelope containing the participant’s allocation. If the 
participant was allocated to capsules, the bottle number would be indicated. 
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Participants allocated to green tea drink were given a month’s supply, and those to 
lycopene diet were given verbal and written advice (each intervention had a patient 
information leaflet). 
To maintain blinding of participants and the study nurse, active and placebo 
capsules were very similar in appearance and provided to the study nurse in sealed 
packs. There was no blinding of participants allocated to dietary modification.  
 
Interventions  
Men in the lycopene dietary group were advised to consume one to two portions of 
preferably cooked tomatoes daily (examples given included a bowl of soup, a heaped 
tablespoon of tomato puree or ketchup, two tinned tomatoes, one medium fresh tomato 
or a glass of tomato juice). Fruits such as watermelon or pink grapefruit were allowed, 
but men were advised that their lycopene content was lower than tomatoes. No foods 
were provided to this group. The other lycopene interventions comprised one daily gel 
capsule of 15 mg tomato-derived extract of lycopene (Solanum lycopersicon L. 
Solanaceae, Lyc-O-Mato®, Lycored Ltd, Beer Sheva, Israel, authorized as dietary 
supplement in the UK) or a matched placebo capsule (Lycored Ltd) taken with a meal 
with water. The green tea (GT) interventions consisted of either drinking at least three 
cups (two UK mugs) of green tea daily (Camellia sinensis L, Theaceae, around 600 
ml/day, green tea bags e.g. PG Tips, Unilever Ltd, provided by the study), or two 300 
mg green tea leaf-derived extract capsules (600 mg/d EGCG, Frutarom Ltd, Reinach, 
Switzerland, authorised as a dietary supplement in the UK) or two matched placebo 
capsules (Frutarom Ltd). The dose was planned as 800 mg/d but was replaced by 600 
mg/d as the supplier only manufactured 300 mg capsules.  
Participants were provided with the first month’s supply of capsules and/or green 
tea bags after randomization, then by post at one and three months (providing a six 
month supply). The research nurse telephoned men at one month to arrange supplies 
and give further advice regarding the interventions. Participants were given weekly 
study logs to aid compliance and to return unused supplies at six months. No foods or 
supplements were prohibited during follow-up. It was planned to advise all groups to 
consume five fruits or vegetables daily but this was removed as it may have hindered 
adherence and acceptability. The design and delivery of participant information was 
informed by the Theory of Planned Behaviour (18) and men received a study fridge 
magnet (19) and there was a study website and newsletter. 
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Participant follow up 
The study nurse recorded socio-demographic information, weight, blood 
pressure and clinical characteristics at recruitment and took non-fasting blood samples 
for PSA and metabolite analyses. Participants completed a paper questionnaire 
following randomization (baseline), at one (postal) and at six months, including a food 
frequency questionnaire (FFQ), smoking status and consumption of alcohol, the 
Hospital Anxiety and Depression Scale (20), Profile of Moods States (21) and 
International Continence Society Male Short Form (22). Additional questions on 
intervention compliance and satisfaction, adverse events in the preceding month and 
dietary changes were completed during follow-up. Participants were given an adverse 
event form with a freepost envelope. The nurse telephoned participants at one month to 
discuss PSA results, interventions and to arrange further supplies (planned as in-
person so PSA and weight were not measured at one month). At the six-month 
appointment the nurse recorded weight and blood pressure, asked about intervention 
adherence and acceptability and took blood samples. Serum samples were separated 
by centrifugation and were stored at -800C until analysis. Body mass index (BMI) used 
height measured in the ProMPT translational study linked to the ProtecT trial (60% 
uptake). Follow-up was completed between 2009 to 2010. 
 
Laboratory assessments 
Lycopene, green tea metabolites and PSA were measured by laboratory staff 
blinded to the allocation (samples were identified by study number). PSA was 
measured at the local hospital which used the UK National Health Service External 
Quality Assessment for PSA. Plasma lycopene was measured by reversed-phase high-
performance liquid chromatography (HPLC) with diode array detection following 
extraction into heptane (23) Plasma catechins, including ()-epicatechin-O-glucuronide, 
() epicatechin-sulfate, EGCG and 5-(dihyroxyphenyl)-ϒ-valerolactone above 1.0 nmol/L 
were measured using HPLC-mass spectrometry (24), (25). 
 
Dietary assessment and analysis 
Dietary intake was assessed using a validated 117-item food frequency 
questionnaire (FFQ) adapted from the UK EPIC study (26) with frequency reported 
across nine categories from “never/less than once per month” to “six or more times per 
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day” for the previous six months (green tea was added in the same format). Analyses 
were conducted as described previously (27) and men were excluded from dietary 
analyses if they were assessed as misreporting energy intake [<800kcal/d or 
>4000kcal/d (28). Alcohol consumption was categorised as above or below national 
recommendations (20 units/week).  
 
Qualitative interviews and analysis (assessment of acceptability and attitudes) 
Men were interviewed at around 6 and 30 weeks after randomization to assess 
intervention acceptability and men’s experience of the interventions (21 men as one 
participant declined after the baseline interview because he felt he had nothing further 
to contribute). Interviews were fully transcribed with baseline results published 
previously (27), (18). 
 
Statistical analysis and sample size calculation 
Primary outcomes were recruitment (randomization rate) and adherence to 
interventions (metabolite levels). It was, therefore, planned to invite around 250 men 
until 126 men were recruited, allowing an anticipated 50% recruitment rate to be 
estimated with 95% confidence interval from 44% to 56%. If 126 men were enrolled, the 
study would have 90% power at the 5% significance level to detect a true 67% increase 
in circulating lycopene and green tea metabolites between the placebo and intervention 
groups (including accommodation for skewed distribution of measures) at six months 
(29). There were no planned interim analyses or stopping guidelines. 
Analyses were conducted on an intention-to-treat basis using Stata 14 
(StataCorp, College Station, TX, USA). Analysis of covariance (ANCOVA) compared 
the log-transformed lycopene levels across lycopene groups at six months adjusted for 
transformed baseline lycopene levels. The exponentiated coefficients are the ratio of 
the geometric mean lycopene levels for active lycopene groups versus placebo 
capsules. Many green tea values were zero so the non-parametric generalized Hodges-
Lehmannn (30) median difference (plasma values) and two-proportion z test (dietary 
reports) were used to compare active and placebo distributions and calculate 95% Cis 
(p-value calculated using the Mann-Whitney test).  
As this was a factorial design, we assessed if there was an interaction between 
lycopene and green tea interventions on six-month lycopene levels. To maximise 
statistical power an ‘active’ group (dietary advice and lycopene capsule groups) was 
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compared with the placebo group. Baseline lycopene was included as a covariate, and 
a dummy variable identifying participants receiving both active lycopene and green tea 
interventions allowed the evidence for an interaction to be evaluated. There was no 
evidence of an interaction between lycopene and green tea on serum lycopene levels 
(p for interaction=0.4), allowing the two interventions to be examined separately. 
ANCOVA was used to compare mean PSA levels, systolic blood pressure and 
weight between intervention groups and placebo for green tea and lycopene at six 
months (corresponding baseline measure of the outcome included as a covariate). The 
distribution of PSA results was highly skewed, so was log-transformed before analysis.   
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Results 
Baseline characteristics and randomization 
Of 469 men approached between December 2009 and May 2010, 133 were 
randomized (28.4%, 95% CI 24.3%-32.7%) giving around 45 participants in each 
lycopene and green tea intervention (consort diagram shown in Figure 1). Of these, 132 
men attended six-month follow-up and 131 (98.5%) gave blood. Table 1 displays the 
baseline characteristics which were well matched by allocated intervention. In addition, 
132 men were of white ethnicity and around half had a managerial occupation. 
 
Primary endpoint-adherence 
Plasma levels at six months were higher in the lycopene capsule and dietary 
advice groups than in the placebo group, although the pre-specified target difference of 
67% was not met (Table 2). Plasma metabolites (EGCG) were higher in the green tea 
drink and capsule groups than the pre-specified target difference and were 
undetectable in the placebo group (Table 2).  
 
Secondary endpoints 
Adherence and dietary intake. Consumption of lycopene-containing foods was highest 
in the dietary advice group with no increase reported in capsule groups (Table 2 and 
Supplementary Figure 1). The proportion of men who reported that they drank green 
tea daily increased to 79% in the tea drinking group at six months but was low and 
unaltered in both capsule groups (Table 2 and Supplementary Figure 1).  
 
Acceptability of interventions. Men stated in interviews that they were confident about 
adhering to their allocated options by quickly and easily establishing a routine to prompt 
them regarding their interventions (Table 3). Routines were assisted by taking capsules 
at meals or with prescribed medicines, whilst green tea drinkers either swapped some 
or all the normal black tea or added green tea drinks e.g. at meals. Men randomized to 
dietary lycopene often added tomatoes to recipes, lunch plates or sandwiches and 
tomato juice was very popular. Men used the ProDiet log but typically discontinued it 
once a routine became established, often in the early days/weeks. Changes to their 
established routine (e.g. holidays or eating out) were the most commonly reported 
barriers to adherence because men forgot or chose not to take interventions with them 
(Table 3). However, many men reported always being able to adhere to the 
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interventions. Some men were surprised that they found green tea palatable and few 
reported significantly disliking it. Men randomized to the lycopene-rich diet often 
reported liking tomatoes and so not minding or finding it enjoyable to increase their 
intake. Most men regarded capsules as ‘supplements’ rather than medication, which 
may have assisted those men who usually disliked taking medication.  
In future, men reported they would prefer capsules to dietary options for green 
tea (102/132, 77.3% preferred capsules; 26/132, 19.7% preferred drink) and lycopene 
(88/132, 66.7% preferred capsules, 41/132, 31.1% preferred dietary changes).  
Around half of the participants intended to continue with a tomato-rich diet (64/132 
48.5%) after the trial and around one third drinking green tea (45/132, 34.1%).  
 
Adverse events. The frequency was generally low except for nocturia (night time urinary 
frequency), insomnia and hypertension which occurred in similar frequencies across all 
groups (Table 4).  
 
Clinical outcomes. PSA levels did not differ between lycopene or green tea groups at 
six months (Table 5). Systolic blood pressure and weight were also comparable 
between all green tea and lycopene groups (Table 5).   
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Discussion  
We report a randomized feasibility trial of green tea and lycopene supplementation in 
men at increased risk of prostate cancer. Nearly one third of men agreed to be 
randomized to lycopene and green tea capsules or dietary options for six months. 
Lycopene and green tea (EGCG) plasma concentrations were higher in participants 
randomized to active capsule or dietary options compared to those randomized to 
placebo capsules. Men’s accounts from interviews revealed that they quickly 
established routines to enhance adherence by incorporating interventions into daily life. 
There were also no major differences in adverse events between groups. PSA, systolic 
blood pressure and weight were comparable between groups, although the trial was not 
designed to identify differences in these endpoints.  
To our knowledge, this is the first placebo-controlled randomized trial of lycopene 
and green tea to include dietary options in men at increased risk of prostate cancer. 
The factorial design maximised the options tested and the standardized ProtecT trial 
prostate cancer detection process ensured a well-characterised ProDiet population. 
Several features helped increase trial quality such as measures to conceal random 
allocation, blinding of participants to capsule options and outcome assessors. Self-
reported consumption of green tea and lycopene-rich foods remained stable in men 
randomized to placebo capsules so contamination was low which implies that 
participant blinding had been successful. Adherence and acceptability were assessed in 
multiple ways, including interviews which evaluated men’s attitudes towards 
interventions. The trial design was pragmatic with no run-in period to remove non-
compliant individuals, dietary restrictions or provision of multi-vitamins (8). 
Recruitment to cancer chemoprevention phase II trials is difficult (2) and was 
lower than planned in this trial, whereas an intensive process was required in the 
SELECT trial to ensure success (8). Adherence was high in ProDiet at six months but 
might have been lower beforehand as there were no interim assessments, although 
interviews indicated that men established routines to enhance adherence. Metabolites 
were not measured from fasted participants as this would have restricted participants 
attending afternoon appointments. Non-fasted measurements may have lowered values 
reported here although they were comparable with lycopene results from several 
studies (31) (32). The dose of green tea could have also been increased above 
600mg/L but was comparable to other prostate cancer prevention studies (15) and the 
equivalent of at least six green tea cups daily (as consumed in Japan) was unlikely to 
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acceptable in the UK. There are some other limitations as the trial recruited previous 
trial participants whom might have been more disposed to adhere to dietary 
interventions than the general population. Participants were also predominantly white 
(as in the ProtecT trial), thus reducing generalisation to other ethnicities with different 
prostate cancer risks. UK Afro-Caribbean men revealed in interviews that they were 
quite heavily involved in food preparation with tomatoes being central to their diet in 
contrast to most ProDiet and ProtecT participants (27), (18), (33). 
Lycopene intake and circulating lycopene were associated with a reduced risk of 
prostate cancer (34), (35) in some meta-analyses, although not universally (11). A 
recent meta-analysis suggested that there was a 3% reduction in prostate cancer 
incidence per mg/day increase in dietary lycopene intake (95% CI 0.94-0.99) (35) which 
matches the increase seen in lycopene dietary consumption reported in this trial. The 
ProDiet dietary lycopene intervention equates to tomato consumption previously 
associated with a reduced prostate cancer risk in ProtecT trial participants (36). 
However, a small placebo-controlled trial of lycopene supplementation in men with 
HGPIN showed no differences in expression of tissue markers for proliferation or cell 
cycle inhibition (MCM-2 and p27, primary endpoints), PSA or cancer rates on re-biopsy 
at six months (37). Lycopene has cardiovascular benefits although not through lowering 
blood pressure so different endpoints would be needed in a definitive trial to measure 
its broader impacts (38). 
Recent systematic reviews suggest a possible role for green tea in prostate 
cancer prevention for HGPIN (39), (14), (40) but evidence is conflicting for overall 
prostate cancer incidence (41). Polyphenols were detected in prostate tissue of men 
with prostate cancer who had consumed green tea (but not black tea or water) prior to 
radical prostatectomy (42) and showed systemic anti-oxidant effects. The second trial of 
green tea capsules for 3-6 weeks before prostatectomy showed no changes in PSA nor 
prostate tissue biomarkers of cell proliferation, apoptosis or angiogenesis which the 
authors hypothesised may have been due to rapid clearance or poor bioaccumulation 
(43). 
The mode of action of most chemoprevention agents remains largely unknown 
and the concept for prostate cancer has been deemed a failure following the SELECT 
and finasteride trials (44). However, preclinical evidence should be used to identify 
biologically active agents to enhance their likelihood of success in clinical trials (2), (45). 
In one example, aspirin has recently been recommended for colorectal cancer 
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prevention in the USA (46).  The UK Add-Aspirin secondary chemoprevention trial with 
five years of aspirin or placebo in men with high risk localised prostate cancer has an 
survival endpoint including prostate cancer and a prostate-specific endpoint of 
biochemical-failure-free survival in around 2,000 patients (47). A phase III trial of 
lycopene, green tea or other chemoprevention agents would need to be of a similar size 
to the prostate cohort of the Add-Aspirin trial with a biological target, incidence 
endpoints and a good safety profile (45).  
In conclusion, men at increased risk of prostate cancer adhered successfully to 
lycopene and green tea dietary and capsule interventions for six months with few side 
effects. Therefore, although recruitment was moderate, dietary interventions can be 
evaluated in clinical effectiveness randomized trials. 
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Table 1. Baseline characteristics of men randomized 
 
aHeight from a ProtecT-linked study which around 60% of participants joined. 
bBlood pressure. 
cAbove 20 units/week (UK male recommendation).
 Lycopene 
 
Dietary advice 
n  = 44 
Lycopene 
capsules   n = 44 
Placebo 
capsules n = 45 
 n 
Mean (SD) 
or % 
n 
Mean (SD) 
or % 
n 
Mean (SD) 
or % 
       
Age, y 44 63.3 (4.4) 44 64.0 (5.8) 45 63.1 (4.3) 
BMIa, kg/m2 18 26.9 (4.9) 23 25.5 (2.8) 20 27.7 (3.6) 
BPb systolic, mmHg 41 144 (16) 43 149 (17) 42 141 (17) 
PSA, ng/mL       
  <3.0 20 45.5 19 43.2 21 46.7 
  3.0-19.9  22 50.0 25 56.8 24 53.3 
Family history of 
prostate cancer 
4 9.1 2 4.6 5 11.1 
Total energy intake, 
kcal/d 
43 2240 (582) 43 2265 (643) 40 2291 (486) 
High alcohol intakec 15 34.1 15 34.1 16 35.5 
  
 Green tea (GT) 
 GT drink n= 45 
GT capsules          
n = 45 
Placebo 
capsules n = 43 
 n 
Mean (SD) 
or % 
n 
Mean (SD) 
or % 
n 
Mean (SD) 
or % 
       
Age, y 45 63.3 (5.4) 45 63.2 (4.0) 43 64.0 (5.1) 
BMI, kg/m2 23 25.5 (2.5) 15 27.5 (4.0) 23 27.1 (4.6) 
BPa systolic, mmHg 42 147 (15) 43 144 (16) 41 144 (20) 
PSA, ng/mL       
 <3.0 19 42.2 22 48.9 19 44.2 
 3.0-19.9  25 55.6 23 51.5 23 53.3 
Family history of 
prostate cancer 
4 9.1 2 4.6 5 11.1 
Total energy intake, 
kcal/d 
41 2459 (530) 44 2194 (561) 41 2146 (586) 
High alcohol intakeb 19 40.2 15 33.3 12 27.9 
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Table 2. Plasma concentrations and dietary intake of lycopene and green tea at baseline 
and six months 
Intervention: plasma 
level or dietary intake 
Baseline            
n = 133  
Six months          
n = 132 
Difference 
from placebo 
at six months 
(95% CI) 
p-
value 
Lycopene     
Plasma lycopene (µmoL/L)     
   Dietary advice (n = 43) 
0.63 (0.46, 
0.98)a 
0.82 (0.68, 1.13)a 
1.28c (1.09, 
1.50) 
0.003 
   Active capsules (n = 42) 0.67 (0.48, 0.82) 0.91 (0.72, 1.13) 1.42 (1.21, 1.66) <0.001 
   Placebo capsules (n = 
42) 
0.53 (0.43, 0.68) 0.60 (0.45, 0.78) - 
- 
     
Daily intake (mg)     
   Dietary advice (n = 38) 
2.00 (0.79, 
3.56)a 
3.26 (1.65, 
16.08)a 
2.82 (1.94, 4.10) <0.001 
   Active capsules (n = 40) 1.50 (0.60, 2.01) 1.26 (0.71, 2.16) 0.99 (0.68, 1.44) 0.952 
   Placebo capsules (n= 
39) 
1.56 (0.73, 2.14) 1.33 (0.68, 2.11) 
- - 
     
Green tea (GT)     
Plasma catechinsd (nM)     
   GT drink (n = 41) 0 (0, 1.1)a 24.9 (0, 51.9)a 
20.0 (7.0, 32.0)e <0.001
f 
   Active capsules (n = 45) 0 (0, 0) 12.3 (0, 27.5) 10.7 (0, 19.0) <0.001 
   Placebo capsules (n = 
41) 
0 (0, 0) 0 (0, 1.6) 
- - 
     
Drinking GT daily     
   GT drink (n = 38) 8 (21)b 30 (79)b 
0.74 (0.59, 
0.88)g 
<0.001 
   Active capsules (n = 41) 5 (12) 5 (12) 
0.07 (-0.05, 
0.19) 
0.279 
   Placebo capsules (n = 
38) 
1 (2) 2 (5) 
- - 
aMedian (interquartile range). 
b Number (percentage).  
cRatio of geometric means (active intervention: placebo), adjusted for baseline values. 
dGreen tea catechin (EGCG: epigallocatechin-O-glucaronide). 
eMedian difference between active intervention and placebo estimated using generalized 
Hodges-Lehmann median difference. 
fp-value estimated using Mann-Whitney test. 
gProportion difference (active intervention: placebo) estimated using Two-proportion z-test. 
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Table 3. Men’s views about adherence and green tea (GT) and lycopene consumption 
Men Adherence and experience of the interventions 
A “Well its its straightforward.  What I did was I kept them [capsules] in a shredded 
wheat box [a breakfast cereal] so every morning when I had my shredded wheat 
I had a couple of tablets” 
B “The pill [lycopene capsules], I just had the pill with my breakfast, my first cup of 
coffee or whatever and the pills were just on the side. I just do it there obviously 
and so it was quite easy to do that. I don’t think I ever dropped out of one of 
those except when I said I went away and I forgot.” 
C “No I don’t say I particularly like taking tablets [GT capsules] but you know but 
as it’s over a period of time then I don’t mind it’s not necessarily a problem. Um I 
take blood pressure tablets anyway so to take one in the morning and one in the 
evening that’s what we had to do it’s not a problem.” 
D “Well, I suppose, initially, they [weekly log] did. After the first month I thought, 
oh, well, they’ve got me into the routine now, so I’m okay.”  
E  “Sometimes when you go on holiday, and things like that, obviously your routine 
changes, so...It’s more difficult when you’re away, you have to...your meals are 
being supplied, things like that, and you’re not in your environment, so it was a 
bit more difficult but...Still managed it, still carried on exactly the same, as near 
as I could…” 
F [GT drink]: “Well, I thought it might still be doing me some good…. I think it’s 
that, so I come to enjoy it. So it’s just, it’s now sort of a way of life” 
G “I do yeah I think I yes. I’ve always eaten a lot of tomatoes in all sorts of different 
ways and I am now aware of it so because I’ve upped the intake for 6 months 
and I’ve concentrated on that sort of effort because if it’s going to be of any help 
you want to make a good job of it and so its it’s in my mind anyway.” 
H “I saw them [capsules] as a health pill, if you’d have said that they were 
prescribed drugs you wanted to try maybe I wouldn’t have joined, I see a lot of 
people on blood pressure pills in my age group and I wouldn’t like to get on them 
myself, it’s things like that you tend to depend on them eventually.” 
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Table 4: Adverse effects at six months 
 
Adverse 
symptom 
in the 
previous 
month 
Lycopene Green tea (GT) 
Dietary 
advice 
N=39 
min. 
Lycopene 
capsules 
 N=40 
min. 
Placebo 
capsules 
N=41 
min. 
GT drink 
N=40 
min. 
GT 
capsules 
 N=41 
min. 
Placebo 
capsules 
N=39 
min. 
n (%) n (%) n (%) n (%) n (%) n (%) 
Nocturia 18 (45) 14 (34) 21 (50) 19 (46) 21 (50) 13 (33) 
Hypertensio
n 
8 (20) 8 (20) 6 (14) 7 (17) 9 (22) 6 (15) 
Insomnia 8 (20) 4 (10) 9 (21) 9 (22) 9 (21) 3 (8) 
Fatigue 6 (15) 3 (7) 10 (24) 2 (5) 10 (24) 7 (18) 
Cramp 7 (18) 3 (8) 3 (7) 6 (15) 3 (7) 4 (10) 
Shortness 
of breath 
3 (8) 3 (7) 4 (10) 1 (2) 1 (2) 8 (20) 
Heartburn 3 (8) 3 (7) 3 (7) 3 (7) 0 (0) 6 (15) 
Headache 1 (3) 2 (5) 6 (14) 1 (2) 3 (7) 5 (13) 
Diarrhoea 0 (0) 1 (2) 3 (7) 1 (2) 1 (2) 2 (5) 
Two participants also reported bad breath (1 in each placebo) and two nausea (1 in 
lycopene capsules and 1 green tea drink). 
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Table 5. Clinical outcomes at six months  
Intervention and clinical 
outcome 
Baseline        
n = 133 
Six months   
n = 132 
Difference from 
placebo at 6 
months (95% CI) 
p-
value 
     
Lycopene     
PSA (ng/ml)     
  Dietary advice (n = 38) 3.1 (2.5, 3.9)a 3.0 (2.3, 4.2)a 0.99 (0.87, 1.11)c 0.817 
  Active capsules (n = 41) 3.2 (2.6, 4.5) 3.2 (2.7, 4.5) 1.01 (0.89, 1.14) 0.897 
  Placebo capsules (n = 42) 3.0 (2.3, 3.8) 3.2 (2.4, 4.3) -  
Weight (kg)   
  
  Dietary advice (n = 42) 85.0 (13.7)b 84.8 (14.1)b 0.0 (-2.1, 2.1)d 0.986 
  Active capsules (n = 38) 81.8 (11.0) 81.5 (11.1) -0.2 (-2.4, 1.9) 0.821 
  Placebo capsules (n= 41) 86.5 (14.7) 86.2 (14.9) -  
Blood pressure         
(systolic mmHg) 
  
  
  Dietary advice (n = 40) 145.2 (15.5)b 143.8 (11.7)b 0.8 (-4.9, 6.4)d 0.786 
  Active capsules (n = 39) 148.6 (17.4) 148.9 (19.3) 4.2 (-1.5, 9.9) 0.148 
  Placebo capsules (n= 42) 141.3 (17.3) 141.1 (13.7) -  
     
Green tea (GT)     
PSA (ng/ml)     
  GT drink (n = 39) 3.1 (2.5, 4.5)a 3.6 (2.4, 4.4)a 1.06 (0.94, 1.20)c 0.357 
  Active capsules (n = 45) 3.1 (2.5, 3.7) 3.1 (2.4, 4.3) 1.02 (0.91, 1.16) 0.698 
  Placebo capsules (n = 37) 3.2 (2.3, 3.9) 3.0 (2.3, 4.1) -  
Weight (kg)     
  GT drink (n = 39) 82.6 (12.6)b 81.5 (14.1)b -0.8 (-2.9, 1.3)d 0.434 
  Active capsules (n = 41) 85.2 (13.4) 85.5 (12.8) 0.7 (-1.4, 2.7) 0.511 
  Placebo capsules (n = 41) 85.8 (14.0) 85.4 (13.7) -  
Blood pressure         
(systolic mmHg) 
  
  
  Dietary advice (n = 40) 146.3 (14.8)b 148.1 (16.3)b 3.9 (-2.6, 10.3)d 0.236 
  Active capsules (n = 41) 144.9 (16.0) 142.6 (13.2) 0.0 (-6.3, 6.4) 0.998 
  Placebo capsules (n= 40) 143.6 (19.7) 142.9 (16.3) - - 
aMedian (interquartile range). 
bMean (standard deviation). 
cRatio of geometric means or ddifference in means between active intervention and 
placebo, adjusted for baseline values. 
